Rottapharm bought by Meda, beating valuation in pulled IPO
![CCM Pharma](https://assets.euromoneydigital.com/dims4/default/017eeed/2147483647/strip/true/crop/264x175+0+0/resize/840x557!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F4a%2F3d%2F09906db4a3f3af3ba884269bbb28%2Fccm-pharma.jpg)
Rottapharm Madaus, the Italian drug firm that pulled its IPO amid tough markets just three weeks ago, has been acquired by a Swedish peer at a valuation nearly 20% above the top of the range in the failed IPO. Meda will finance the €2.3bn deal through the debt and equity markets.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: